{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:08:50Z","timestamp":1784239730964,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejso.2026.111948","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:01:21Z","timestamp":1781200881000},"page":"111948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy and surgical decision-making in Lynch syndrome\u2013associated colorectal cancer: Implications for personalized management and guideline revision"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0974-1852","authenticated-orcid":false,"given":"Saeed","family":"Rafii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5701-4268","authenticated-orcid":false,"given":"Ali N.","family":"Chamseddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaid O.","family":"Al-Shamsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faek","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.111948_bib1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1055-9965.EPI-16-0693","article-title":"Prevalence and penetrance of major genes and polygenes for colorectal cancer","volume":"26","author":"Win","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejso.2026.111948_bib2","first-page":"5248","article-title":"A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer","volume":"58","author":"Boland","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejso.2026.111948_bib3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","article-title":"Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database","volume":"67","author":"M\u00f8ller","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ejso.2026.111948_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.ejso.2026.111948_bib5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/gut.2010.228056","article-title":"Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery","volume":"60","author":"Parry","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.ejso.2026.111948_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/SLA.0b013e3181f20bd2","article-title":"Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria","volume":"252","author":"Kalady","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.111948_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejso.2026.111948_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejso.2026.111948_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejso.2026.111948_bib10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2026.111948_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study","volume":"33","author":"Chalabi","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib13","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.111948_bib14","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-021-02084-x","article-title":"Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?","volume":"22","author":"Tonello","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ejso.2026.111948_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.dld.2022.09.015","article-title":"Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR\/MSI-H colorectal cancer, a BIG-RENAPE collaboration","volume":"55","author":"Barraud","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejso.2026.111948_bib17","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.2003.04.060","article-title":"Role of DNA mismatch repair defects in the pathogenesis of human cancer","volume":"21","author":"Peltom\u00e4ki","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib18","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"17","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejso.2026.111948_bib20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.gastro.2008.01.015","article-title":"Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers","volume":"134","author":"Schwitalle","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejso.2026.111948_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2016.10.009","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"17","author":"Giannakis","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejso.2026.111948_bib22","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejso.2026.111948_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejso.2026.111948_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejso.2026.111948_bib25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","article-title":"Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms","volume":"121","author":"Sahin","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2026.111948_bib26","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM199805213382101","article-title":"Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease","volume":"338","author":"Aaltonen","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.111948_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib28","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1200\/JCO.2016.71.0012","article-title":"Cancer susceptibility gene mutations in individuals with colorectal cancer","volume":"35","author":"Yurgelun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/EDBK_349557","article-title":"Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability\/mismatch repair deficiency in 2022","volume":"42","author":"Andr\u00e9","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejso.2026.111948_bib30","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.111948_bib31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"La","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib33","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455907","article-title":"Durable response to pembrolizumab in hepatic metastasis from colonic carcinoma with Lynch syndrome: a case report","volume":"15","author":"Xue","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejso.2026.111948_bib35","first-page":"389","article-title":"Complete pathological response following neoadjuvant pembrolizumab in a patient with dMMR peritoneal metastasis from colon cancer: a case report","volume":"13","author":"Somashekhar","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejso.2026.111948_bib36","article-title":"Neoadjuvant immunotherapy in MSI-H\/dMMR colorectal cancer: from clinical evidence to standard of care","volume":"15","author":"Pinto","year":"2023","journal-title":"Cancers (Basel"},{"key":"10.1016\/j.ejso.2026.111948_bib37","article-title":"Pathological complete response after monotherapy with immune checkpoint inhibitors for bifocal colon cancer in a patient with Lynch syndrome and situs inversus totalis: a case report","volume":"16","author":"Feng","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejso.2026.111948_bib38","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient Colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.111948_bib39","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"De Gooyer","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2026.111948_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.ejso.2026.111948_bib41","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.ccell.2025.09.004","article-title":"Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H\/dMMR colon cancer: a randomized phase 1b study","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejso.2026.111948_bib42","article-title":"NEOPRISM-CRC: neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR\/MSI-high colorectal cancer","volume":"42","author":"Shiu","year":"2024","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejso.2026.111948_bib43","article-title":"Efficacy and safety of neoadjuvant monoimmunotherapy with PD-1 inhibitor for dMMR\/MSI-H locally advanced colorectal cancer: a single-center real-world study","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejso.2026.111948_bib44","first-page":"494","article-title":"Neoadjuvant immunotherapy in non-metastatic colorectal cancer: a systematic review and meta-analysis","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1540751","article-title":"The neoadjuvant immunotherapy for non-metastatic mismatch repair-deficient colorectal cancer: a systematic review","volume":"16","author":"Cui","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejso.2026.111948_bib46","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair\u2013deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.111948_bib47","series-title":"FDA grants breakthrough therapy designation to dostarlimab for dMMR\/MSI-H locally advanced rectal cancer","author":"Food","year":"2023"},{"key":"10.1016\/j.ejso.2026.111948_bib48","article-title":"Watch-and-wait strategy for DNA mismatch repair-deficient\/microsatellite instability-high rectal cancer with a clinical complete response after neoadjuvant immunotherapy: an observational cohort study","volume":"32","author":"Wang","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.04.052","article-title":"Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stability and microsatellite instability-high, locally advanced rectal cancer","volume":"31","author":"Yuki","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001499","article-title":"RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study","volume":"8","author":"Cohen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejso.2026.111948_bib51","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00675","article-title":"Prevalence and clinical implications of mismatch repair-proficient colorectal cancer in patients with Lynch syndrome","author":"Ranganathan","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10689-012-9568-9","article-title":"Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors","volume":"12","author":"Sourrouille","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1016\/j.ejso.2026.111948_bib53","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2026.111948_bib54","article-title":"Clinical and molecular characterization of microsatellite stable (MSS) tumors in patients with lynch syndrome (LS)","volume":"41","author":"Harrold","year":"2023","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejso.2026.111948_bib55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10689-012-9591-x","article-title":"EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients","volume":"12","author":"Ligtenberg","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1016\/j.ejso.2026.111948_bib56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/cge.14670","article-title":"Mismatch repair proficient colorectal adenocarcinoma in two patients with Lynch syndrome","volume":"107","author":"Khandakar","year":"2025","journal-title":"Clin Genet"},{"key":"10.1016\/j.ejso.2026.111948_bib57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12029-025-01203-1","article-title":"Microsatellite stable colorectal tumours in patients with Lynch syndrome: a case report and systematic review analysing clinical features and implications for immunotherapy","volume":"56","author":"Kapoulitsa","year":"2025","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.ejso.2026.111948_bib58","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO.26 study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib59","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41416-024-02696-6","article-title":"First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer\u2014the randomised METIMMOX trial","volume":"130","author":"Ree","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2026.111948_bib60","first-page":"1562","article-title":"Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6 -Methylguanine\u2013DNA methyltransferase\u2013silenced metastatic colorectal cancer: the MAYA trial","volume":"40","author":"Morano","year":"2022","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejso.2026.111948_bib61","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and Bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejso.2026.111948_bib62","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.3390\/cancers13112638","article-title":"Mechanisms of immune escape and resistance to checkpoint inhibitor therapies in mismatch repair deficient metastatic colorectal cancers","volume":"13","author":"Amodio","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejso.2026.111948_bib63","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.cgh.2025.06.040","article-title":"Identifying risk factors for metachronous colorectal cancer in Lynch syndrome","volume":"24","author":"H\u00fcneburg","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2026.111948_bib64","article-title":"Metachronous colorectal cancer risks after extended or segmental resection in MLH1, MSH2, and MSH6 Lynch syndrome: multicentre study from the prospective Lynch syndrome database","volume":"112","year":"2025","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.111948_bib65","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/DCR.0000000000000802","article-title":"Subtotal colectomy for Colon cancer reduces the need for subsequent surgery in Lynch syndrome","volume":"60","author":"Renkonen-Sinisalo","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ejso.2026.111948_bib66","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10689-017-0062-2","article-title":"Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis","volume":"17","author":"Malik","year":"2018","journal-title":"Fam Cancer"},{"key":"10.1016\/j.ejso.2026.111948_bib67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/DCR.0b013e3181c702de","article-title":"Comparison of extended colectomy and limited resection in patients with Lynch syndrome","volume":"53","author":"Natarajan","year":"2010","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ejso.2026.111948_bib68","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/codi.12868","article-title":"Segmental extended colectomy in the management of hereditary nonpolyposis colorectal cancer: a systematic review and meta\u2010analysis","volume":"17","author":"Heneghan","year":"2015","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ejso.2026.111948_bib69","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S2468-1253(23)00228-5","article-title":"Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study","volume":"8","author":"Eikenboom","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2026.111948_bib70","series-title":"NCCN clinical practice guidelines in oncology: genetic\/familial high-risk assessment: colorectal","author":"Network","year":"2024"},{"key":"10.1016\/j.ejso.2026.111948_bib71","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib72","series-title":"Recent advances in Lynch syndrome: diagnosis, treatment, and cancer prevention","first-page":"101","author":"Yurgelun","year":"2018"},{"key":"10.1016\/j.ejso.2026.111948_bib73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ajg.2014.435","article-title":"ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes","volume":"110","author":"Syngal","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejso.2026.111948_bib74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/DCR.0000000000000785","article-title":"Clinical practice guidelines for the surgical treatment of patients with Lynch syndrome","volume":"60","author":"Herzig","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ejso.2026.111948_bib75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/gutjnl-2019-319915","article-title":"Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)\/Association of Coloproctology of Great Britain and Ireland (ACPGBI)\/United Kingdom Cancer Genetics Group (UKCGG","volume":"69","author":"Monahan","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ejso.2026.111948_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111948_bib77","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ajg.2014.186","article-title":"Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society task force on colorectal cancer","volume":"109","author":"Giardiello","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejso.2026.111948_bib78","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/bjs.11902","article-title":"European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender","volume":"108","author":"Sepp\u00e4l\u00e4","year":"2021","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.111948_bib79","series-title":"Clinical practice guidelines for the prevention, early detection and management of colorectal cancer","article-title":"Cancer council Australia colorectal cancer guidelines working party","author":"Macrae","year":"2021"},{"key":"10.1016\/j.ejso.2026.111948_bib80","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/diagnostics11030544","article-title":"Microsatellite instability in colorectal cancer liquid biopsy\u2014current updates on its potential in non-invasive detection, prognosis and as a predictive marker","volume":"11","author":"Tieng","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejso.2026.111948_bib81","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/jnci\/djae060","article-title":"Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome","volume":"116","author":"Song","year":"2024","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2026.111948_bib82","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.csbj.2021.08.037","article-title":"Sensitive detection of microsatellite instability in tissues and liquid biopsies: recent developments and updates","volume":"19","author":"Yu","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.ejso.2026.111948_bib83","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41417-023-00721-z","article-title":"Detection of (pre)cancerous colorectal lesions in Lynch syndrome patients by microsatellite instability liquid biopsy","volume":"31","author":"Boeri","year":"2024","journal-title":"Cancer Gene Ther"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326005676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326005676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:45:33Z","timestamp":1784238333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326005676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0748798326005676"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111948","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy and surgical decision-making in Lynch syndrome\u2013associated colorectal cancer: Implications for personalized management and guideline revision","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111948"}}